Biomarker Identification & Selection Services

Are you currently facing challenges in identifying reliable and specific biomarkers for your drug development programs or clinical trials? Creative Biolabs helps you accelerate biomarker discovery and validation through advanced multi-omics analysis and high-throughput screening platforms. Our professional biomarker identification and selection services are designed to provide you with the critical data needed to advance your research and development, ultimately leading to more effective and personalized therapeutic strategies.

Introduction

Cancer biomarkers broadly refer to molecules indicating the presence of cancer or the body’s response to it. They are detectable in blood, urine, or other fluids via PCR, ELISA, and similar assays. These biomarkers include genetic, epigenetic, proteomic, glycomic, and imaging types, used in cancer diagnosis, prognosis, and epidemiology.

Fig.1 Types of currently discovered tumor biomarkers.^1,3

In a narrower sense, especially for chimeric antigen receptor T cell (CAR-T) therapy, cancer biomarkers typically refer to proteins that distinguish tumor cells from normal ones and serve as key targets for immune attack. Effective CAR-T biomarkers usually:

• Play a role in cancer development and correlate with disease progression or improvement;
• Show high or unique expression on cancerous or precancerous tissues compared to normal cells, ensuring specificity and safety-particularly true for mutant proteins uniquely expressed by tumors.

Biomarker Identification and Selection Services at Creative Biolabs

At Creative Biolabs, we provide almost all the discovered cancer targets and novel ones for the evaluation of CAR-T therapy. Like AFP for liver cancer, BCR-ABL for chronic myeloid leukemia, BRCA1/BRCA2 for breast/ovarian cancer, BRAF V600E for melanoma/colorectal cancer, CA-125 for ovarian cancer, CA19.9 for pancreatic cancer, CEA for colorectal cancer, EGFR for non-small-cell lung carcinoma, HER-2 for breast cancer, KIT for gastrointestinal stromal tumor, PSA for prostate cancer, S100 for melanoma. Since we can develop CAR-T therapy aiming at any target in our growing database with more than 1,000 cancer biomarkers, the most professional and sophisticated services are at Creative Biolabs.

Creative Biolabs offers the world-leading custom CAR service with the most advanced techniques and years of experience to establish a solid platform for CAR production.

• Recommend the most applicable target according to the specific type of cancer and customs requirements, or design subsequent and further technique service based on the designated target;
• Screen originally for novel potential target based on customized conditions, which is an advanced optional service with relatively higher technique requirement and price.

Service Process

Featured Services

Key Advantages

• Comprehensive Multi-Omics Analysis: We integrate genomics, transcriptomics, and proteomics to uncover biomarkers and reveal disease mechanisms.
• Customized Project Design: Projects are tailored in close collaboration to meet specific goals-target disease, sample type, and data format.
• Advanced Technology: We use high-throughput sequencing, mass spectrometry, and proprietary bioinformatics for sensitive, specific detection.
• Flexible Services: From screening to validation, we offer scalable solutions to fit your timeline, scope, and budget.

Representative Data

Summary: This study developed a high-affinity monoclonal antibody against the tumor biomarker preferentially expressed antigen in melanoma by immunizing mice with a specific fragment. The antibody detected endogenous and membrane-bound forms in biomarker-positive cells via western blot and flow cytometry. Bio-layer interferometry identified its epitope, and mutational analysis revealed key hydrophobic residues and cysteines essential for binding.

Fig.2 Binding analysis of proteins using ELISA.^2,3

FAQs

Why Choose Us?

Creative Biolabs leverages a multi-disciplinary team of oncologists, molecular biologists, and data scientists to provide a holistic approach to biomarker discovery. Our proprietary high-throughput platforms and advanced bioinformatics pipeline allow for the rapid and accurate identification of even low-abundance biomarkers. This expertise is supported by published data demonstrating the effectiveness of our methods in identifying novel biomarkers. We ensure a high level of customization and support throughout your project, from initial design to final data interpretation.

How to Contact Us

Creative Biolabs' Biomarker Identification and Selection Services are designed to accelerate your research and provide the clear, actionable data you need to succeed. From discovery to validation, we are your trusted partner in precision medicine.

For more information or to discuss your specific project, please reach out to our team.

References

1. Zhou, Yue et al. "Tumor biomarkers for diagnosis, prognosis and targeted therapy." Signal transduction and targeted therapy vol. 9,1 132. 20 May. 2024, https://doi.org/10.1038/s41392-024-01823-2
2. Sivaccumar, Jwala Priyadarsini et al. "Development of a New Highly Selective Monoclonal Antibody against Preferentially Expressed Antigen in Melanoma (PRAME) and Identification of the Target Epitope by Bio-Layer Interferometry." International journal of molecular sciences vol. 22,6 3166. 20 Mar. 2021, https://doi.org/10.3390/ijms22063166. Distributed under Open Access License CC BY 4.0, without modification.